Qx Therapeutics Inc. has received FDA authorization of “Study May Proceed” with a Phase 2 Clinical Trial of QXT-101 for the prevention and treatment of PGD in lung transplant recipients.”
Leading (Yale) Bioscience Entrepreneurs Sign Leases at New 113,000 SF Elm City Bioscience Center in New Haven
Osmol Therapeutics Initiates IND Enabling Studies to Develop First Therapy for Prevention of Chemotherapy-Induced Peripheral Neuropathy
Gennao Bio Closes $40 Million Series A Financing to Develop Pipeline of Targeted Nucleic Acid Therapeutics
